The pricey hepatitis C drugs represent a good problem, but a problem nonetheless, in that they represent a cure for the disease, but the price is so high.
Leah Binder has found that employers are furious and worried about drug prices in general, but the hepatitis C drugs in particular. Sovaldi is driving costs for these purchases, but more than that the fact that there is a drug out there that costs so much is a risky prospect.
“They don’t know what’s going to happen next year,” she said. “What’s the next drug that’s going to come along and just throw their whole benefits program out of whack? And I don’t know how long employers are going to keep in that game.”
The discussion moved on to the 21st Century Cures Act and how that would impact the pharmceutical industry. And while finding more cures is a good thing, Matt Salo is unhappy with 2 main parts of the legislation. First, it extends market exclusivity for approved drugs, which is what keeps prices high he said. Second, the legislation also speeds innovative therapies to the market, which sounds good in theory, but can have serious repercussions, Matt Salo said. Getting drugs to the market sooner means curtailing clinical trials and patient safety issues, which is dangerous for his beneficiaries, which in Medicaid includes the oldest, sickest, frailest, most medically complex patients.
Austin Frakt, PhD, also voiced concerns about the extended exclusivities.
“I think market exclusivity is clearly the mechanism by which prices initially start quite high and therefore we as a society have an obligation to look at that and we have a right to manage it in some fashion,” he said.
The way to manage prices hasn’t been decided, and each idea has strengths, limitations, and implications for research and development, which all need to be weighed, but it’s still better than simply granting market exclusivity and allowing companies to set whatever price they want, Dr Frakt said.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More